• Thomson Reuters (TSX:TRI) has revealed the expanded vision for its professional-grade GenAI assistant, CoCounsel
  • CoCounsel will provide customers with a new way to access Thomson Reuters products through a single GenAI assistant
  • Applications include legal, tax, risk and fraud and media
  • Shares of Thomson Reuters are down 0.25 per cent to C$209.92 as of 12:49 p.m. ET

Thomson Reuters (TSX:TRI) has revealed the expanded vision for its professional-grade GenAI assistant, CoCounsel.

The company stated in a news release that CoCounsel will provide customers with a new way to access Thomson Reuters products through a single GenAI assistant, with applications including legal, tax, risk and fraud and media.

CoCounsel is an artificial intelligence (AI) assistant that handles complex tasks with human language understanding. CoCounsel will provide high-quality information, maintain multiple work tasks and keep context and memory across different tasks that customers use every day.

Our unique combination of resources means we can deliver on our vision of providing professionals a new, human-centric point of access to our suite of Thomson Reuters products,” David Wong, CEO of Thomson Reuters, said in a statement. As our products continue to expand and improve, the customer experience will remain centred in our GenAI assistant as CoCounsel learns new skills and capabilities – unlocking productivity and becoming the way professionals work.”

In time, it is believed that CoCounsel will be able to link Thomson Reuters products across its portfolio.

Thomson Reuters also stated it will use its GenAI platform to create future GenAI skills that will be introduced into products across every business segment served under the CoCounsel brand.

Thomson Reuters is a multi-purpose company that serves professionals across legal, tax, accounting, compliance, government and media.

Shares of Thomson Reuters Corp. (TSX:TRI) are down 0.25 per cent to C$209.92 as of 12:49 pm ET.

Join the discussion: Find out what everybody’s saying about this stock on the Thomson Reuters Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online

Optimi Health to advance psychedelic clinical trials

Optimi Health (CSE:OPTI) signs letter of intent with ATMA Journey Centers to advance its psilocybin extract into a psilocybin clinical trial.

@ the Bell: TSX falls in energy sell off

Canada’s main stock index loses ground from sagging commodity prices, but tech shares provide most of the gains on the TSX on Wednesday.